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We report three simultaneous measles outbreaks 
with 112 confirmed cases in three Health Regions of 
Portugal, from February to April 2018. The mean age of 
cases was 30 years, 79% worked in a healthcare set-
ting and 87% were vaccinated. Genotype B3 was iden-
tified in 84 cases from the three outbreaks. Primary 
cases in each outbreak were imported. Several cases 
presented with modified measles, highlighting the 
importance of rethinking the measles case definition 
for vaccinated cases.
We present preliminary findings and implemented 
control measures of three simultaneous measles out-
breaks that occurred in Portugal between February and 
April 2018. One of the outbreaks took place in a hospi-
tal and represented a particular challenge for epidemi-
ological and laboratory investigations as a substantial 
number of vaccinated healthcare workers (HCWs) 
developed benign clinical signs and symptoms of mea-
sles. We discuss these findings and highlight the need 
to expand the European Union (EU) measles case defi-
nition, in order to increase sensitivity in case capture 
among vaccinated individuals with modified measles 
and who do not meet the current European Union (EU) 
case definition.
Case definition 
Measles case definition used for epidemiological sur-
veillance in Portugal is based on the EU case definition 
[1]. A possible case is any person who meets clinical 
criteria (i.e. fever, maculopapular rash, and any of 
cough/coryza/conjunctivitis); a probable case is any 
person who meets clinical criteria and has an epide-
miological link to a confirmed case; a confirmed case 
is any possible case with laboratory evidence of infec-
tion with measles wild virus (i.e. detection of viral RNA 
in a biological sample and/or a positive IgM result in 
serum), determined by the World Health Organization 
(WHO)-certified national reference laboratory for mea-
sles and rubella National Institute of Health – Instituto 
Nacional de Saúde Doutor Ricardo Jorge, Lisbon [2]. 
Cases are discarded when clinical, epidemiological 
or laboratory criteria are not met, taking into account 
vaccination history and risk of measles infection in the 
community or abroad, following WHO criteria [3].
However, symptoms in modified measles cases are 
masked meaning that cases do not present with the 
usual signs and symptoms of classic measles, this 
making a clinical diagnosis more challenging. Modified 
measles mainly affects young adults who have been 
vaccinated, suggesting that they could have subop-
timal protection against measles whether it be from 
insufficient number of vaccination doses or that the 
immunity to disease has waned over time as revealed 
in the National Serological Survey (2015/2016) [4]. 
Therefore, the case definition used during this out-
break was expanded to increase sensitivity: clinical 
criteria included any person with a maculopapular 
rash, or fever or any of the following three symptoms: 
cough, coryza, conjunctivitis. Epidemiological criteria 
included any person with a link to the hospital or with 
a confirmed measles case.
Outbreak description
On 9 March 2018, a laboratory-confirmed measles case 
was notified by INSA. It corresponded to an unvacci-
nated French citizen, recently arrived in the North 
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Health region from the Aquitaine Region, where a mea-
sles outbreak has been ongoing [5]. Following the labo-
ratory notification, the case was clinically notified on 
12 March in the National System for Epidemiological 
Surveillance (Sistema Nacional de Vigilância 
Epidemiológica, SINAVE), which is an integrated clini-
cal and laboratory electronic system of mandatory noti-
fication. This case was the source of infection for three 
additional cases in close relatives that either lived 
with or visited the case; all had been vaccinated with 
two measles-mumps-rubella (MMR) doses. No further 
cases were related to this chain of transmission.
On 13 March 2018, the clinical director of a hospital in 
Oporto reported 24 suspected measles cases among 
the hospital’s HCWs to public health authorities. 
All suspected cases had a link with the Emergency 
Department and presented with maculopapular rash, 
tachycardia, low fever and headache. The following 
day, INSA confirmed the first two cases along with a 
third, who was not a HCW and was admitted to another 
hospital in the city. Epidemiological investigations led 
to the retrospective identification of the imported pri-
mary case, who was an unvaccinated individual from 
Italy who arrived in Oporto 10 days before the symp-
tom onset and who went to the Emergency Department 
when they developed a rash. Overall, there were 103 
confirmed measles cases associated with this primary 
case. Most cases were HCWs (n = 87; 84.5%), of which 
10 (11.5%) were vaccinated with one dose of a mea-
sles-containing vaccine, 66 (75.9%) with two doses, 
four (4.6%) with three doses, and seven (8.0%) were 
unvaccinated.
On 26 and 28 March, two cases with history of recent 
travel to two different African countries and both hav-
ing a stopover at the same airport on the same day dur-
ing the incubation period (and evidence of remaining in 
the same waiting room) were notified in SINAVE. One of 
the cases was vaccinated with two MMR doses and did 
not infect further cases. The other case was unvacci-
nated and infected three additional cases, one at work 
and two contacts in a hospital Emergency Department.
From 12 March until 31 May, a total of 440 suspected 
measles cases were notified in SINAVE, of which 
112 (25.5%) were laboratory-confirmed in INSA, 303 
(68.9%) were discarded and 25 (5.7%) were still under 
investigation.  Figure 1shows the distribution of all 
confirmed measles cases by date of symptom onset 
and chain of transmission. Overall, 47 (45.6%) cases 
in this chain of transmission had benign clinical signs 
and symptoms of measles. History of vaccination was 
verified from individuals’ medical charts or from the 
national immunisation registry.
Of the 112 confirmed measles cases the mean age 
was 30 years (SD: 7.7) and 65 cases were female. 
Preliminary findings show that 111 confirmed measles 
Figure 1
Confirmed measles cases by date of symptom onset, chain of transmission and vaccination status, Portugal, 11 February–28 
April 2018 (n = 112)
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Source: Direção-Geral da Saúde, Sistema Nacional de Vigilância Epidemiológica.
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Table 1
Characteristics of measles cases by chain of transmission Portugal, 11 February − 28 April 2018 (n = 112)
France-related chain of 
transmission
Italy-related chain of 
transmission
Africa-related chain of 
transmission Total
n n n n %
Total 4 103 5 112 100.0
Sex
Female 2 62 1 65 58.0
Male 2 41 4 47 42.0
Age group (years)
< 1 0 0 0 0 0.0
1–9 0 1 0 1 0.9
10–19 0 0 0 0 0.0
20–29 2 52 1 55 49.1
30–39 2 40 3 45 40.2
40–49 0 8 1 9 8.0
50–59 0 2 0 2 1.8
≥ 60 0 0 0 0 0.0
Vaccination status
Not vaccinated 1 13 1 15 13.4
1 dose 0 12 2 14 12.5
2 doses 3 74 2 79 70.5
3 doses 0 4 0 4 3.6
Occupation
Non-Healthcare workers 3 16 4 23 20.5
Doctors 1 33 0 34 30.4
Nurses 0 20 0 20 17.9
Allied professionals 0 15 1 16 14.3
Medical/Nursing students 0 18 0 18 16.0
Other Healthcare workers 0 1 0 1 0.9
Measles symptoms
Maculopapular rash + Fever + Cough/
Coryza/Conjunctivitis 1 56 5 62 55.4
Maculopapular rash only 2 11 0 13 11.6
Fever only 0 2 0 2 1.8
Maculopapular rash + Fever 1 23 0 24 21.4
Maculopapular rash + Cough 0 1 0 1 0.9
Maculopapular rash + Coryza 0 7 0 7 6.2
Fever + Coryza 0 1 0 1 0.9
Fever + Cough + Coryza 0 1 0 1 0.9
Cough + Coryza 0 1 0 1 0.9
Laboratory results
Detection of viral RNA 3 80 5 88 78.6
Positive IgM 0 3 0 3 2.7
Increase of both IgM and IgG in a pair of 
samples 1 7 0 8 7.1
Increase of IgM in a pair of samples 0 3 0 3 2.7
Increase of IgG in a pair of samples 0 10 0 10 8.9
Genotype
B3 2 78 4 84 64.1
Source: Direção-Geral da Saúde, Sistema Nacional de Vigilância Epidemiológica, Instituto Nacional de Saúde Dr Ricardo Jorge.
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cases occurred in adults (≥ 18 years), with an age range 
of 20–54 years and one case in a 3-year-old child vac-
cinated with one MMR dose (Table 1). Among the 112 
confirmed cases, 83 (74.1%) were vaccinated with two 
or more doses of a measles-containing vaccine. Fifty 
(44.6%) confirmed cases did not meet the clinical cri-
teria from the EU case definition; among them, 24 of 
50 had a maculopapular rash and fever as clinical pres-
entation and 13 cases (11.6%) only had a maculopapu-
lar rash. Twenty-one cases (18.8%) were confirmed 
through laboratory results of second samples, where an 
increase of either IgM, IgG or both was verified (Table 
1). Among the 88 cases where viral RNA was detected, 
84 cases could be genotyped. Genotype B3 was identi-
fied in cases from all the three chains of transmission, 
although the four cases from the Africa-related chain 
of transmission had a 5 nucleotide difference from the 
genotype B3 identified in the other two chains of trans-
mission, which was phylogenetically indistinct.
The measles outbreaks affected three of the seven 
Portuguese Health Regions (Figure 2), with the major-
ity of cases 107 of 112 (95.5%) reported in the North 
Health Region. 
Control measures
Following the laboratory notification of the first con-
firmed measles case, DGS issued a warning to health-
care services that was followed by recommendations 
and guidelines regarding diagnosis, early detection 
and response to measles cases, within the scope of the 
National Measles Elimination Programme [6].
In order to control the outbreak on a local level and mit-
igate transmission outside the healthcare setting, an 
Emergency Response Team comprising of hospital and 
public health professionals was created in the affected 
hospital in Oporto [7]. A vaccination point within the 
hospital was set-up allowing for rapid vaccination of 
close contacts and unvaccinated individuals.
During the outbreaks, all suspected measles cases 
reported were investigated and control measures were 
promptly implemented to contain further transmission. 
Local public health teams undertook extensive contact 
tracing for all suspected measles cases. Surveillance 
and control measures included immediate isolation of 
suspected cases, verification of immunisation status 
of close contacts and administration of prophylactic 
immunoglobulin or MMR vaccine, whenever necessary. 
In addition, control measures were complemented with 
broader public health measures, including the dissemi-
nation of key documents to support prevention and 
control measures [8,9] and raising public awareness 
about the importance of vaccination through numerous 
reports in the national media as well as a large media 
campaign. Daily press releases and epidemiologi-
cal bulletins were issued by DGS while the outbreaks 
lasted.
Figure 2
Incidence rate of confirmed measles cases per 100,000 
population by health region, Portugal, 11 February−28 
April 2018 (n = 112)
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Epidemiológica. Note: Map developed by GeoSaúde (http://www.
geosaude.dgs.pt/).
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As the primary or index cases did not originate in 
Portugal or had stayed in another country during 
their incubation period, the director-general of Health 
in Portugal notified the Health Authorities from 
these countries regarding the cases, following the 
International Health Regulations [10].
Discussion
Following 12 years without endemic measles transmis-
sion, Portugal experienced two measles outbreaks 
in 2017 [11] and, so far, three measles outbreaks in 
2018. In two of these transmission mainly occurred in 
the community setting, whereas one mainly occurred 
in a healthcare setting. The high coverage of measles 
vaccination and the timely implementation of control 
measures allowed for the rapid containment of mea-
sles and interruption of all chains of transmission. The 
outbreaks were declared over on 10 June 2018 and 
since 29 April 2018 no new cases have been detected 
[12]. The Immediate isolation of cases, extensive con-
tact tracing and vaccination were crucial to contain the 
outbreak in the Oporto hospital and avoid its spread to 
the community.
Vaccination or acquired immunity after illness consti-
tute adequate protection against measles [13]. Since 
the measles vaccine was introduced in the Portuguese 
National Immunisation Programme in 1974, the country 
has achieved a consistent and sustained high immuni-
sation coverage against measles (> 95%) [11,14].
HCWs are at higher risk of measles exposure because 
the high intensity of the exposure and subsequent 
transmission to vulnerable patients [15]. According to 
the National Measles Elimination Programme, HCWs 
are recommended to receive two doses of measles vac-
cine (either single measles-containing vaccine or MMR) 
or to have evidence of previous measles infection [6]. 
However, measles outbreaks in healthcare settings 
are becoming more frequent in the European Region 
[15-18]. Countries, such as Portugal, which maintained 
a high vaccination coverage for many years and had 
eliminated measles, are at greater risk of modified 
measles cases emerging during outbreaks. This is due 
to suboptimal protection against measles, either from 
insufficient number of vaccine doses or waning immu-
nity from the vaccine over time (as indicated by the 
National Serological Survey 2015/2016). Modified mea-
sles mainly affect young adults who were adequately 
vaccinated but with the last dose of the vaccine admin-
istered more than 10 years prior.
In one chain of transmission, a hospital cluster was 
identified and most cases were HCWs vaccinated with 
two or more doses of MMR vaccine. This was described 
in other outbreaks [18] and may be related to waning 
of vaccine-induced immunity in the absence of natural 
boosting by the wildtype virus [19].
Modified measles cases has been described in vac-
cinated individuals [20,21]. In the outbreaks reported 
here, this was the case in 50 of 112 (44.6%) confirmed 
cases. Early findings of modified measles led us to 
expand the case definition initially in place in order to 
increase sensitivity. Interestingly, 5 of 112 (4.5%) con-
firmed cases did not have a maculopapular rash, and 
their symptoms would have been easily mistaken for 
other clinical conditions if they were not investigated 
in the context of a measles outbreak. Also, laboratory 
confirmation was only possible due to the collection 
of second serum samples in 21 of 112 cases, where an 
increase of IgM or IgG antibodies was verified [22].
The outbreaks described here, which included a num-
ber of cases with modified measles and a large number 
of cases among vaccinated HCWs, highlight the need 
for further investigation in order to recommend inno-
vative approaches in future outbreaks: Nearly half of 
these cases would not have been identified using the 
current EU case definition. Thus, in light of these new 
findings and in order to increase sensitivity in case cap-
ture in the context of an outbreak, it would be impor-
tant to develop an additional case classification suited 
for a community with high vaccination coverage with 
epidemiological criteria, that may lead to the definition 
of risk levels for public health intervention according 
to the type of exposure or depending to exposure to 
cases of reinfection.
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